Pharmaceuticals
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
* End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure strategies * End-of-treatment data from ENHANCE did not demonstrate improved HBsAg loss rates compared to ...
2026-07-03 08:00
5262
SK bioscience Launches AI-Powered Initiative to Reduce Uncertainty in Vaccine-Development Decisions
* SK bioscience was selected to lead the Gates Foundation-funded ROTOR project, establishing a global collaboration framework. * SK bioscience, PATH, Slalom, and SK AX will jointly develop an AI-powered platform for evidence-based clinical development decision-making. * The project will supp...
2026-07-02 20:00
3814
Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery
Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration a...
2026-07-02 10:16
4084
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
SUZHOU, China and MÖLNDAL, Sweden, July 2, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with Madrigal Pharmaceuticals, Inc. (Madrigal, NASDAQ: MDGL) announce the successful...
2026-07-02 09:29
3544
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
SHANGHAI, July 1, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN) to jointly advance the clinical development of a novel I...
2026-07-02 09:00
3500
Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-Class Single-Domain Antibody-Based BBB-Crossing Technology for CNS Diseases
CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, today announced a strategic collaboration with Lonza to develop best-in-class single-domain antibody–base...
2026-07-02 08:05
3624
Vitafoods Asia 2026: Science-Backed Botanicals and Next-Generation Probiotics Take Centre Stage
Leading Companies Present Science-Backed Solutions Addressing Antimicrobial Resistance, Digestive Health, and Wellness Through Advanced Probiotics and Clinical Botanicals BANGKOK, July 1, 2026 /PRNewswire/ -- As global healthcare confronts the urgent challenge of antimicrobial resistance, Vitafo...
2026-07-01 18:37
3104
Tsingke Biotech Hosts Shanghai Salon on Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeutics
SHANGHAI, June 30, 2026 /PRNewswire/ -- Tsingke Biotech recently hosted the Oligonucleotide Drug Salon at the Hilton Shanghai Zhangjiang, bringing together experts from academia, biopharmaceutical companies, investment firms, and industry service organizations to discuss technological innovation,...
2026-06-30 22:17
3571
Shantha Biologics Announces Cartridge Fill-Finish Collaboration
HYDERABAD, India, June 30, 2026 /PRNewswire/ -- Shantha Biologics today announced that it has entered into an outsourcing agreement with Novo Nordisk to provide cartridge fill-finish manufacturing services in India. The agreement with Novo Nordisk reflects Shantha Biologics' continued focus on h...
2026-06-30 21:47
3273
Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth
* Advanced environmental performance through renewable energy transition and enhanced carbon transparency * Strengthened sustainability management and supply chain engagement across the healthcare value chain INCHEON, South Korea, June 30, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.K...
2026-06-30 19:00
3162
METiS TechBio and Boulevard Bio Enter Global License Agreement for Trispecific T-cell Engager
HONG KONG and NEW YORK, June 30, 2026 /PRNewswire/ -- METiS TechBio (7666.HK), a leading AI-driven drug delivery innovation company, today announced it has entered into an exclusive global licensing agreement with Boulevard Bio ("Boulevard"), a U.S. biotechnology company backed by Deerfield Manag...
2026-06-30 17:37
2299
EirGenix Showcases Dual-Track Biosimilars and CDMO Strategy in U.S. Market Push at BIO 2026
SAN DIEGO, June 30, 2026 /PRNewswire/ -- At BIO 2026, EirGenix presented its comprehensive HER2-positive breast cancer biosimilar portfolio and highlighted its integrated one-stop contract development and manufacturing organization (CDMO) service platform. The company actively pursued U.S. market...
2026-06-30 13:36
2573
Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...
2026-06-30 12:00
3011
Xellar Raises $50 Million Series A Financing to Build the Future of 3D Bio Intelligence
Financing will accelerate the development of human-relevant biological data infrastructure, virtual cell technologies, and next-generation drug discovery BOSTON, June 29, 2026 /PRNewswire/ -- Xellar Biosystems today announced the closing of $50 million in Series A and A+ financing to advance its ...
2026-06-30 10:06
2161
Alebund Pharmaceuticals (09637.HK) Debuts on the HKEx Main Board
Deepening Its Commitment to Kidney Disease and Accelerating Toward Becoming a Global Leader in Renal Innovation SHANGHAI, June 29, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a biopharmaceutical company focused on kidney dise...
2026-06-29 20:00
5780
Key Milestone Achieved: NDA for Sumecigrel Capsule, an Antiplatelet Innovative Drug by Vcare PharmaTech, Officially Accepted
NANJING, China, June 26, 2026 /PRNewswire/ -- Recently, the NDA for Sumecigrel Capsule (formerly known as Vicagrel), a Class 1 innovative antiplatelet drug developed by Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech), has been officially accepted by the NMPA. The drug has now entered the NDA...
2026-06-26 22:30
4128
CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union
* Recommendation follows an Article 20 non-pharmacovigilance procedure * Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the...
2026-06-26 21:06
4792
Everest Medicines Announces China NMPA Acceptance of the Biologics License Application for LEROCHOL® in Adults with Hypercholesterolemia
SHANGHAI, June 26, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that China's National Medical Products...
2026-06-26 10:08
7048
Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer
Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as a strategy to address therapeut...
2026-06-25 22:51
5117
CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand
* Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand. * This partnership marks sugemalimab's fifth internati...
2026-06-25 17:44
6302
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 315 media titles]
2026-08-28 09:01Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
[Picked up by 314 media titles]
2026-08-27 10:25
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 309 media titles]
2026-09-02 08:30Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 309 media titles]
2026-09-02 12:17
Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 302 media titles]
2026-09-01 11:00
Most Read
Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
2026-08-27 10:25
17500